Does Rallies show 13F holders for ABOS?

Yes. Rallies tracks hedge fund and 13F ownership data for ABOS, including fund names, share counts, latest tracked quarter, and position changes when available.

Is ABOS research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ABOS. It does not provide personalized investment advice.

ABOS (Acumen Pharmaceuticals, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Acumen Pharmaceuticals, Inc. Common Stock (ABOS) is a publicly traded Healthcare sector company. As of May 21, 2026, ABOS trades at $2.37 with a market cap of $157.46M and a P/E ratio of -1.16. ABOS moved +9.22% today. Year to date, ABOS is +18.69%; over the trailing twelve months it is +121.70%. Its 52-week range spans $0.86 to $3.60. Analyst consensus is buy with an average price target of $8.00. Rallies surfaces ABOS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns ABOS stock?

Hedge funds tracked by Rallies that own ABOS include Exoduspoint Capital. The latest tracked quarter is Mar 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Acumen Pharmaceuticals, Inc. Common Stock.

ABOS Key Metrics

Key financial metrics for ABOS
Metric	Value
Price	$2.37
Market Cap	$157.46M
P/E Ratio	-1.16
EPS	$-2.00
Dividend Yield	0.00%
52-Week High	$3.60
52-Week Low	$0.86
Volume	1.52K
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-121.33M
Gross Margin	0.00%

Top Hedge Funds Holding ABOS

Exoduspoint Capital holds 25.62K shares of ABOS, changed -20.57% as of Mar 31, 2024.

Latest ABOS News

Acumen Pharmaceuticals Confirms Phase 2 Sabirnetug Trial on Track, Data by Late 2026 — May 12, 2026
Acumen Pharmaceuticals closes $35.8M financing, completes ALTITUDE-AD enrollment — Mar 26, 2026
Acumen raises $35.75M for EBD program, sabirnetug Phase 2 readout due late 2026 — Mar 26, 2026
Acumen to Present JCR-Backed Sabirnetug Brain Delivery and Biomarker Data at AD/PD — Mar 3, 2026

Recent ABOS Insider Trades

Meisner Derek M sold 2.09K (~$6.81K) on Mar 6, 2026.
Meisner Derek M sold 9.41K (~$28.31K) on Feb 27, 2026.
Meisner Derek M sold 2.67K (~$8.02K) on Jan 28, 2026.

ABOS Analyst Consensus

2 analysts cover ABOS: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $8.00.

Common questions about ABOS

Who owns ABOS stock?: Hedge funds tracked by Rallies that own ABOS include Exoduspoint Capital. The latest tracked quarter is Mar 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Acumen Pharmaceuticals, Inc. Common Stock.
Does Rallies show 13F holders for ABOS?: Yes. Rallies tracks hedge fund and 13F ownership data for ABOS, including fund names, share counts, latest tracked quarter, and position changes when available.
Is ABOS research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ABOS. It does not provide personalized investment advice.